|Day Low/High||42.12 / 42.55|
|52 Wk Low/High||32.64 / 42.97|
The company discusses potential share repurchases and its acquisition strategy.
SoftBank's $3.3 billion deal for Fortress topped the notable transactions this week.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Hologic, Inc. has taken over the #121 spot from Marsh & McLennan Companies Inc.
HCV viral load test now available alongside HIV-1 assay and women's health menu on the fully automated Panther system
Wall Street smashes records again on Tuesday, closing at all-time highs for its fourth consecutive session.
Wall Street hold small gains on Tuesday after Federal Reserve Chair Janet Yellen plays the part of both dove and hawk.
Wall Street is mixed on Tuesday morning after Federal Reserve Chair Janet Yellen champions the strength of the U.S. economy.
-Expands Hologic's Scientific and Commercial Expertise into Large, Adjacent Medical Device Segment Growing at Double-Digit Rate -
The most ethnically and gender diverse boards may surprise you.
--Smaller 6 mm Diameter and Product Updates Are Designed to Enhance Patient Comfort and Improve Physician Ease-of-Use--
- Strengthens Efforts to Build a Sustainable Growth Company -
Here are Wednesday's top research calls, including upgrades for Agco, AthenaHealth and Hologic, and a downgrade for Oshkosh.
--High-performing HIV viral load test now available alongside broad women's health menu on the fully automated Panther® system--
Hologic and Grifols have worked together since 1998 building a blood screening business, and now Hologic will sell its share to Grifols.
--New products spotlight Hologic's leading tomosynthesis technology, including the world's first dedicated prone biopsy system with 2D or 3D™ imaging--
Here's a window into what institutional investors may be doing and how to profit from that.